Search details
1.
Development of LIBRA-seq for the guinea pig model system as a tool for the evaluation of antibody responses to multivalent HIV-1 vaccines.
J Virol
; 98(1): e0147823, 2024 Jan 23.
Article
in English
| MEDLINE | ID: mdl-38085509
2.
Homologous Ad26.COV2.S vaccination results in reduced boosting of humoral responses in hybrid immunity, but elicits antibodies of similar magnitude regardless of prior infection.
PLoS Pathog
; 19(11): e1011772, 2023 Nov.
Article
in English
| MEDLINE | ID: mdl-37943890
3.
Hemagglutinin stalk-specific Fc-mediated functions are associated with protection against influenza-illness after seasonal influenza vaccination in pregnant women.
J Infect Dis
; 2024 May 14.
Article
in English
| MEDLINE | ID: mdl-38743692
4.
Comparing the immune abnormalities in MIS-C to healthy children and those with inflammatory disease reveals distinct inflammatory cytokine production and a monofunctional T cell response.
Clin Immunol
; 259: 109877, 2024 02.
Article
in English
| MEDLINE | ID: mdl-38141746
5.
Functional consequences of allotypic polymorphisms in human immunoglobulin G subclasses.
Immunogenetics
; 75(1): 1-16, 2023 02.
Article
in English
| MEDLINE | ID: mdl-35904629
6.
Shared N417-Dependent Epitope on the SARS-CoV-2 Omicron, Beta, and Delta Plus Variants.
J Virol
; 96(15): e0055822, 2022 08 10.
Article
in English
| MEDLINE | ID: mdl-35867572
7.
Hinge length contributes to the phagocytic activity of HIV-specific IgG1 and IgG3 antibodies.
PLoS Pathog
; 16(2): e1008083, 2020 02.
Article
in English
| MEDLINE | ID: mdl-32092122
8.
IgG3 enhances neutralization potency and Fc effector function of an HIV V2-specific broadly neutralizing antibody.
PLoS Pathog
; 15(12): e1008064, 2019 12.
Article
in English
| MEDLINE | ID: mdl-31841557
9.
HIV-specific Fc effector function early in infection predicts the development of broadly neutralizing antibodies.
PLoS Pathog
; 14(4): e1006987, 2018 04.
Article
in English
| MEDLINE | ID: mdl-29630668
10.
South African HIV-1 subtype C transmitted variants with a specific V2 motif show higher dependence on α4ß7 for replication.
Retrovirology
; 12: 54, 2015 Jun 24.
Article
in English
| MEDLINE | ID: mdl-26105197
11.
Safety and immunogenicity of booster vaccination and fractional dosing with Ad26.COV2.S or BNT162b2 in Ad26.COV2.S-vaccinated participants.
PLOS Glob Public Health
; 4(4): e0002703, 2024.
Article
in English
| MEDLINE | ID: mdl-38603677
12.
Novavax NVX-COV2373 triggers neutralization of Omicron sub-lineages.
Sci Rep
; 13(1): 1222, 2023 01 21.
Article
in English
| MEDLINE | ID: mdl-36681693
13.
Despite delayed kinetics, people living with HIV achieve equivalent antibody function after SARS-CoV-2 infection or vaccination.
Front Immunol
; 14: 1231276, 2023.
Article
in English
| MEDLINE | ID: mdl-37600825
14.
Antibody-dependent cellular cytotoxicity against SARS-CoV-2 Omicron sub-lineages is reduced in convalescent sera regardless of infecting variant.
Cell Rep Med
; 4(1): 100910, 2023 01 17.
Article
in English
| MEDLINE | ID: mdl-36603577
15.
Homologous Ad26.COV2.S vaccination results in reduced boosting of humoral responses in hybrid immunity, but elicits antibodies of similar magnitude regardless of prior infection.
medRxiv
; 2023 Mar 15.
Article
in English
| MEDLINE | ID: mdl-36993404
16.
Infection pre-Ad26.COV2.S-vaccination primes greater class switching and reduced CXCR5 expression by SARS-CoV-2-specific memory B cells.
NPJ Vaccines
; 8(1): 119, 2023 Aug 12.
Article
in English
| MEDLINE | ID: mdl-37573434
17.
Durability of ChAdOx1 nCoV-19 (AZD1222) vaccine and hybrid humoral immunity against variants including omicron BA.1 and BA.4 6 months after vaccination (COV005): a post-hoc analysis of a randomised, phase 1b-2a trial.
Lancet Infect Dis
; 23(3): 295-306, 2023 03.
Article
in English
| MEDLINE | ID: mdl-36273491
18.
Functional HIV-1/HCV cross-reactive antibodies isolated from a chronically co-infected donor.
Cell Rep
; 42(2): 112044, 2023 02 28.
Article
in English
| MEDLINE | ID: mdl-36708513
19.
Safety and immunogenicity of booster vaccination and fractional dosing with Ad26.COV2.S or BNT162b2 in Ad26.COV2.S-vaccinated participants.
medRxiv
; 2023 Nov 20.
Article
in English
| MEDLINE | ID: mdl-38045321
20.
Antibody class-switching as a strategy to improve HIV-1 neutralization.
Trends Mol Med
; 28(11): 979-988, 2022 11.
Article
in English
| MEDLINE | ID: mdl-36117072